The global herpes labialis treatment market is estimated to be valued at USD 1,238.7 million in 2025 and is projected to reach USD 1,887.1 million by 2035, registering a CAGR of 4.3% over the forecast ...

A single dose of the antiviral baloxavir marboxil (Xofluza) led to a lower incidence of influenza virus transmission to household contacts compared with placebo, a phase IIIb randomized trial showed.